Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response

Journal of Affective Disorders

Volumn 133, Issue 1-2, 2011, Pages 165-173

  Xu, Zhi ^a   Zhang, Zhijun ^a   Shi, Yanyan ^b   Pu, Mengjia ^a   Yuan, Yonggui ^a,b   Zhang, Xiangrong ^a   Li, Lingjiang ^c  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Antidepressant; Depression; Dopamine; Genetic polymorphism; Norepinephrine; Stress

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; PROTEIN SLC6A2; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CATECHOLAMINE NERVE CELL; CHILDHOOD INJURY; CHILDHOOD TRAUMA QUESTIONNAIRE SHORT FORM; CHINESE; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; EARLY LIFE STRESS; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HAMILTON SCALE; HAPLOTYPE; HUMAN; LIFE EVENTS SCALE; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; DEPRESSION; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; HUMANS; LIFE CHANGE EVENTS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; MULTIFACTOR DIMENSIONALITY REDUCTION; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; STRESS, PSYCHOLOGICAL; SYNAPTIC TRANSMISSION;

EID: 80051664842     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2011.04.011     Document Type: Article

References (73)

1. B. Arias, A. Serretti, C. Lorenzi, C. Gastó, R. Catalán, and L. Fañanás Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin J. Affect. Disord. 90 2-3 2006 251 256 (Pubitemid 43185979)
2. Association American Psychiatric Washington: Diagnostic and Statistical Manual of Mental Disorders 4th ed 1994 American Psychiatric Press
3. M. Bauer, P.C. Whybrow, J. Angst, M. Versiani, H.J. Möller, and World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder World J. Biol. Psychiatry 3 1 2002 5 43
4. B.T. Baune, C. Hohoff, K. Berger, A. Neumann, S. Mortensen, T. Roehrs, J. Deckert, V. Arolt, and K. Domschke Association of the COMT val158met variant with antidepressant treatment response in major depression Neuropsychopharmacology 33 4 2008 924 932 (Pubitemid 351252697)
5. R.H. Belmaker, and G. Agam Major depressive disorder N. Engl. J. Med. 358 1 2008 55 68 2008 Jan 3
6. Bemstein, D.P., Fink, L., 1998. Childhood Trauma Questionnaire A retrospective self-report Manual. The Psychological Corporation, Harcourt Brace & Company, San Antonio.
7. F. Benedetti, C. Colombo, A. Pirovano, E. Marino, and E. Smeraldi The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting Psychopharmacology (Berl). 203 1 2009 155 160
8. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing Journal of the Royal Statistical Society B 57 1995 289 300
9. B. Bondy, and P. Zill Pharmacogenetics and psychopharmacology Curr. Opin. Pharmacol. 4 1 2004 72 78 (Pubitemid 38145841)
10. H. Bönisch, and M. Brüss The norepinephrine transporter in physiology and disease Handb. Exp. Pharmacol. 175 2006 485 524
11. H.G. Brunner Monoamine oxidase and behaviour Ann. Med. 27 4 1995 431 432
12. J.D. Bukh, C. Bock, J.D. Bukh, C. Bock, M. Vinberg, T. Werge, U. Gether, and L.V. Kessing No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment Eur. Neuropsychopharmacol. 20 2010 327 335
13. J. Chen, B.K. Lipska, N. Halim, Q.D. Ma, M. Matsumoto, S. Melhem, B.S. Kolachana, T.M. Hyde, M.M. Herman, J. Apud, M.F. Egan, J.E. Kleinman, and D.R. Weinberger Functional analysis of genetic variation in catechol-O- methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain Am. J. Hum. Genet. 75 5 2004 807 821 (Pubitemid 39390488)
14. L. Diatchenko, G.D. Slade, A.G. Nackley, K. Bhalang, A. Sigurdsson, I. Belfer, D. Goldman, K. Xu, S.A. Shabalina, D. Shagin, M.B. Max, S.S. Makarov, and W. Maixner Genetic basis for individual variations in pain perception and the development of a chronic pain condition Hum. Mol. Genet. 14 1 2005 135 143 (Pubitemid 40123469)
15. K. Domschke, C. Hohoff, L.S. Mortensen, T. Roehrs, J. Deckert, V. Arolt, and B.T. Baune Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression Prog Neuropsychopharmacol Biol Psychiatry. 32 1 2008 224 228
16. F. Dudbridge Pedigree disequilibrium tests for multilocus haplotypes Genet Epidemiol. 25 2003 115 121 (Pubitemid 37064867)
17. E. Dremencov, I. Gispan-Herman, M. Rosenstein, A. Mendelman, D.H. Overstreet, J. Zohar, and G. Yadid The serotonin-dopamine interaction is critical for fast-onset action of antidepressant treatment: in vivo studies in an animal model of depression Prog Neuropsychopharmacol Biol Psychiatry. 28 1 2004 141 147 (Pubitemid 37548506)
18. W. El Hage, J.F. Powell, and S.A. Surguladze Vulnerability to depression: what is the role of stress genes in gene × environment interaction? Psychol. Med. 39 2009 1407 1411
19. M. Elovainio, M. Jokela, M. Kivimäki, L. Pulkki-Råback, T. Lehtimäki, N. Airla, and L. Keltikangas-Järvinen Genetic variants in the DRD2 gene moderate the relationship between stressful life events and depressive symptoms in adults: cardiovascular risk in young Finns study Psychosom. Med. 69 5 2007 391 395 (Pubitemid 46987880)
20. M.A. Enoch, C.A. Hodgkinson, Q. Yuan, P.H. Shen, D. Goldman, and A. Roy The influence of GABRA2, childhood trauma, and their interaction on alcohol, heroin, and cocaine dependence Biol. Psychiatry 67 2010 20 27
21. W. Fu, and S. Yao Initial Reliability and Validity of Childhood Truama Questinnaire(CTQ-SF) Apllied in Chinese College Students Chinese Journal of Clinical Psychology. 13 2005 40 42
22. A.A. Gershon, T. Vishne, and L. Grunhaus Dopamine D2-like receptors and the antidepressant response Biol. Psychiatry 61 2 2007 145 153 (Pubitemid 46072787)
23. C. Gundlah, N.Z. Lu, and C.L. Bethea Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei Psychopharmacology (Berl). 160 3 2002 271 282 (Pubitemid 34230679)
24. G. Guo, and K.H. Tillman Trajectories of depressive symptoms, dopamine D2 and D4 receptors, family socioeconomic status and social support in adolescence and young adulthood Psychiatr. Genet. 19 1 2009 14 26
25. M. Hamilton A rating scale for depression J. Neurol. Neurosurg. Psychiatry 23 1960 56 62
26. S. Horstmann, and E.B. Binder Pharmacogenomics of antidepressant drugs Pharmacol. Ther. 124 2009 57 73
27. L. Hosák Role of the COMT gene Val158Met polymorphism in mental disorders: a review Eur. Psychiatry 22 5 2007 276 281 (Pubitemid 47088199)
28. G.S. Hotamisligil, and X.O. Breakefield Human monoamine oxidase A gene determines levels of enzyme activity. Am. J. Hum. Genet. 49 2 1991 383 392 (Pubitemid 21891684)
29. S.Y. Huang, M.T. Lin, W.W. Lin, C.C. Huang, M.J. Shy, and R.B. Lu Association of monoamine oxidase A (MAOA) polymorphisms and clinical subgroups of major depressive disorders in the Han Chinese population World J. Biol. Psychiatry 10 4 Pt 2 2009 544 551
30. M. Jansson, S. McCarthy, P.F. Sullivan, P. Dickman, B. Andersson, L. Oreland, M. Schalling, and N.L. Pedersen MAOA haplotypes associated with thrombocyte-MAO activity BMC Genet. 20 6 2005 46
31. R. Keers, R. Uher, P. Huezo-Diaz, R. Smith, S. Jaffee, M. Rietschel, N. Henigsberg, D. Kozel, O. Mors, W. Maier, A. Zobel, J. Hauser, D. Souery, A. Placentino, E.R. Larsen, M. Dmitrzak-Weglarz, B. Gupta, F. Hoda, I. Craig, P. McGuffin, A.E. Farmer, and K.J. Aitchison Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project Pharmacogenomics J. 2010 Epub ahead of print
32. A.H. Kemp, E. Gordon, J. Rush, M. Leanne, and M. Williams Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging and genetic measures CNS Spectr. 13 2008 1066 1086
33. H. Kim, S.W. Lim, S. Kim, J.W. Kim, Y.H. Chang, B.J. Carroll, and D.K. Kim Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression JAMA. 296 13 2006 1609 1618 (Pubitemid 44511608)
34. J. Kirchheiner, K. Nickchen, J. Sasse, M. Bauer, I. Roots, and J. Brockmöller A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment Pharmacogenomics J. 7 1 2006 48 55
35. N.A. Kocabas, C. Faghel, M. Barreto, S. Kasper, S. Linotte, J. Mendlewicz, M. Noro, P. Oswald, D. Souery, J. Zohar, and I. Massat The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study Int. Clin. Psychopharmacol. 25 4 2010 218 227
36. A. Kugaya, N.M. Seneca, P.J. Snyder, S.A. Williams, R.T. Malison, R.M. Baldwin, J.P. Seibyl, and R.B. Innis Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration Neuropsychopharmacology 28 2 2002 413 420
37. T. Laasonen-Balk, H. Viinamäki, J.T. Kuikka, M. Husso-Saastamoinen, J. Lehtonen, and J. Tiihonen 123I-beta-CIT binding and recovery from depression. A six-month follow-up study Eur. Arch. Psychiatry Clin. Neurosci. 254 3 2004 152 155 (Pubitemid 39304464)
38. G. Lambert, M. Johansson, H. Agren, and P. Friberg Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders Arch. Gen. Psychiatry 57 8 2000 787 793 (Pubitemid 30650115)
39. X.Y. Lou, G.B. Chen, L. Yan, J.Z. Ma, J. Zhu, R.C. Elston, and M.D. Li A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence Am. J. Hum. Genet. 80 2007 1125 1137 (Pubitemid 47579348)
40. F.W. Lohoff, and T.N. Ferraro Pharmacogenetic considirations in the treatment of psychiatric disorders Expert Opin. Pharmacother. 11 2010 423 439
41. L. Mandelli, and E. Marino Interaction between SERTPR and stressful life events on response to antidepressant treatment Eur. Neuropsychopharmacol. 19 2009 64 67
42. L. Mandelli, E. Marino, A. Pirovano, R. Calati, R. Zanardi, C. Colombo, and A. Serretti Interaction between SERTPR and stressful life events on response to antidepressant treatment European Neuropsychopharmacology 19 2009 64 67
43. P.T. Männistö, and S. Kaakkola Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors Pharmacol. Rev. 51 1999 593 628
44. F.J. McMahon, S. Buervenich, D. Charney, R. Lipsky, A.J. Rush, A.F. Wilson, A.J. Sorant, G.J. Papanicolaou, G. Laje, M. Fava, M.H. Trivedi, S.R. Wisniewski, and H. Manji Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment Am. J. Hum. Genet. 78 5 2006 804 814
45. E. Michaelovsky, D. Gothelf, M. Korostishevsky, A. Frisch, M. Burg, M. Carmel, T. Steinberg, D. Inbar, A. Apter, and A. Weizman Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS Int. J. Neuropsychopharmacol. 11 3 2008 351 363 (Pubitemid 351482504)
46. M.J. Millan Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 110 2 2006 135 370
47. M. Miniati, and P. Rucci Clinical characteristics and treatment outcome of depression in patients with and without a history of emotional and physical abuse J. Psychiatr. Res. 44 2009 302 309
48. J. Moncrieff, and I. Kirsch Efficacy of antidepressants in adults BMJ. 331 2005 155 159
49. R.T. Mulder, P.R. Joyce, C.M. Frampton, S.E. Luty, and P.F. Sullivan Six months of treatment for depression: outcome and predictors of the course of illness Am. J. Psychiatry 163 1 2006 95 100 (Pubitemid 43050109)
50. L. Musazzi, A. Mallei, D. Tardito, S.H. Gruber, A. El Khoury, G. Racagni, A.A. Mathé, and M. Popoli Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression J. Psychiatr. Res. 44 2009 511 520
51. A.G. Nackley, S.A. Shabalina, J.E. Lambert, M.S. Conrad, D.G. Gibson, A.N. Spiridonov, S.K. Satterfield, and L. Diatchenko Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs PLoS One 4 4 2009 5237
52. C.B. Nemeroff, and W.W. Vale The neurobiology of depression: inroads to treatment and new drug discovery J. Clin. Psychiatry 7 2005 5 13 (Pubitemid 41345489)
53. D.J. Nutt The role of dopamine and nerepinephrine in depression and antidepressant treatment J. Clin. Psychiatry 67 suppl 6 2006 3 8 (Pubitemid 44078106)
54. D. Pickar, and K. Rubinow Pharmacogenomics of psychiatric disorders Trends Pharmacol. Sci. 22 2001 75 83 (Pubitemid 32146485)
55. J.L. Rausch, M.E. Johnson, Y.J. Fei, J.Q. Li, N. Shendarkar, H.M. Hobby, V. Ganapathy, and F.H. Leibach Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome Biol. Psychiatry 51 2002 723 732 (Pubitemid 34450808)
56. A. Schosser, and S. Kasper The role of pharmacogenetics in the treatment of depression and anxiety disorders Int. Clin. Psychopharmacol. 24 2009 277 288
57. A. Serretti, and P. Olgiati Depression: Mind Body. 3 1 2009 19 31
58. A. Serretti, F. Benedetti, R. Zanardi, and E. Smeraldi The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments Progress in Neuro-psychopharmacology & Biological Psychiatry. 29 2005 1074 1084 (Pubitemid 41080134)
59. P.R. Shiroma, Y.E. Geda, and D.A. Mrazek Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry Pharmacogenomics 11 9 2010 1305 1330
60. L.J. Smith, J.A. Henderson, C.W. Abell, and C.L. Bethea Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques Neuropsychopharmacology 29 11 2004 2035 2045 (Pubitemid 39486555)
61. N. Sun, and Y. Xu The combined effect of norepinephrine transporter gene and negative life events in major depression of Chinese Han population J. Neural Transm. 115 2008 1681 1686
62. A. Szegedi, D. Rujescu, A. Tadic, M.J. Müller, R. Kohnen, H.H. Stassen, and N. Dahmen The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression Pharmacogenomics J. 5 1 2005 49 53 (Pubitemid 40220617)
63. A. Tadić, M.J. Müller, D. Rujescu, R. Kohnen, H.H. Stassen, N. Dahmen, and A. Szegedi The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B 3 2007 325 331 (Pubitemid 46642022)
64. B.D. Thombs, and D.P. Bernstein A validation study of the Dutch Childhood Trauma Questionnaire-Short Form: factor structure, reliability, and known-groups validity Child Abuse Negl. 33 2009 518 523
65. R. Tranter, C. O'Donovan, P. Chandarana, and S. Kennedy Prevalence and outcome of partial remission in depression J. Psychiatry Neurosci. 27 4 2002 241 247 (Pubitemid 34988904)
66. S.J. Tsai, Y.T. Gau, C.J. Hong, Y.J. Liou, Y.W. Yu, and T.J. Chen Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients J. Affect. Disord. 113 1-2 2009 183 187
67. C.H. Wetzel, B. Hermann, C. Behl, E. Pestel, G. Rammes, W. Zieglgänsberger, F. Holsboer, and R. Rupprecht Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor Mol Endocrinol. 12 1998 1441 1451 (Pubitemid 128496204)
68. Z. Xu, Z.J. Zhang, Y.Y. Shi, M.J. Pu, Y.G. Yuan, X.R. Zhang, L.J. Li, and G.P. Reynolds Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response J Psychopharmacol 2011 Epub ahead of print
69. D.S. Yang, and Y.L. Zhang Life Event Scales (LES) X.D. Wang, X.L. Wang, H. Ma, Rating Scales for Mental Health Chinese Mental Health Journal 1999 101 106
70. K. Yoshida, H. Takahashi, H. Higuchi, M. Kamata, K. Ito, K. Sato, S. Naito, T. Shimizu, K. Itoh, K. Inoue, T. Suzuki, and C.B. Nemeroff Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms Am. J. Psychiatry 161 9 2004 1575 1580 (Pubitemid 39201453)
71. Y.W. Yu, S.J. Tsai, C.J. Hong, T.J. Chen, M.C. Chen, and C.W. Yang Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response Neuropsychopharmacology 30 9 2005 1719 1723 (Pubitemid 43086029)
72. A. Zangen, R. Nakash, D.H. Overstreet, and G. Yadid Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens Psychopharmacology (Berl). 155 4 2001 434 439 (Pubitemid 32523115)
73. P. Zill, T.C. Baghai, R. Engel, P. Zwanzger, C. Schüle, C. Minov, S. Behrens, R. Bottlender, M. Jäger, R. Rupprecht, H.J. Möller, M. Ackenheil, and B. Bondy Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response Am. J. Med. Genet. B Neuropsychiatr. Genet. 120B 1 2003 85 89 (Pubitemid 37059383)